CME 8 Session - EANM'14

Radionuclide Therapy: "Read with the Experts" – Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumours

Educational objectives:
  1. To be able to identify suitable patients with neuroendocrine tumours having a good prospect regarding a positive response after peptide receptor radionuclide therapy
  2. Knowing the relevant imaging procedures and examinations that have to be made pretherapeuticlly
  3. To set actual state- of-the-art knowledge on planning a PRRT
  4. To know the respective advantages and disadvantages of Y-90 and Lu-177 labelled peptides
  5. To set actual state-of-art knowledge on adequate protocols using the respective peptides
This session is aimed to physicians taking responsibility for selection, planning, treating and response evaluation in patients with neuroendocrine tumours undergoing peptide receptor radionuclide therapy. After the session the audience should independently be able to identify patients that are suitable for PRRT. The participants should know the steps that are necessary to plan a PRRT. They should be able to decide whether a Y-90 or Lu-177 labelled peptide is more suitable and be able to choose an adequate therapy protocol. The audience should know about the response rates that can be expected.

Key Words:
Peptide Receptor Radionuclide Therapy, Neuroendocrine Tumours, Y-90, Lu-177, Patient Selection, Therapy Planning, Response Evaluation
Teaser Video
A short description by Flavio Forrer, member of the EANM Radionuclide Therapy Committee

User action required
If you have the permission to view this publication, please log in.